Kidney and Hypertension Section, E.P. Joslin Research Laboratory, Joslin Diabetes Center, Boston, MA, USA.
Clinical Endpoint Committee, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 02215, USA.
Diabetes Res Clin Pract. 2019 Apr;150:1-7. doi: 10.1016/j.diabres.2019.02.015. Epub 2019 Feb 20.
Accurate dosing of medications for glycemic control is a challenge for clinicians in diabetic patients with kidney disease. Diminishing glomerular filtration rates are associated with decreased renal clearance of insulin and increased prevalence of hypoglycemic episodes. Measurement of glucose/C peptide ratios may be useful to guide dosing in those patients who receive powerful insulin secretogogues as glomerular function decreases with age and disease.
In order to determine the relationship between glucose, C-peptide and renal function, we reviewed the records of patients with type 2 diabetes followed in our kidney hypertension clinic who met the following criteria: age 35-90 years, requirement of medications to control glycemia, at least 4 simultaneous measurements of C peptide, HbA1c, creatinine and blood glucose.
87 patients (67 males, 20 females), ages 67.1 ± 10.6 years, BMI 32.5 ± 5.2, A1c 8.2 ± 1.2%, eGFR 73 ± 27.2 ml/min, had glucose/C-peptide ratios 60.7 ± 46.4. 59% of the total group were taking insulin secretogogues. Patients were divided into groups based upon mean eGFR and use or absence of insulin secretogogues. Glucose C-peptide ratios were lowest in the quartile of patients with the lowest eGFR (<50 ml/min).
Diminished renal function and advanced age are associated with the lowest glucose/C-peptide ratios, independent of achieved glycemic control. With similar use of secretogogues, glucose/C-peptide ratio were lower when eGFR was ≤49 ml/min compared to >50-80 ml/min. Use of secretogogues was associated with decreased glucose/C-peptide levels. In patients with reduced renal function (eGFR < 50 ml/min), use of insulin secretogogues may be associated with lower glucose/C-peptide ratios associated with higher risks for hypoglycemic reactions.
对于患有肾脏疾病的糖尿病患者,准确控制药物剂量以控制血糖是临床医生面临的挑战。肾小球滤过率降低与胰岛素肾清除率降低和低血糖发作的发生率增加有关。随着年龄和疾病的发展,肾小球功能下降,测量血糖/ C 肽比值可能有助于指导那些接受强力胰岛素分泌剂的患者进行剂量调整。
为了确定血糖、C 肽与肾功能之间的关系,我们回顾了在我们的肾脏高血压诊所就诊的 2 型糖尿病患者的记录,这些患者符合以下标准:年龄 35-90 岁,需要药物控制血糖,至少有 4 次同时测量 C 肽、HbA1c、肌酐和血糖。
87 名患者(67 名男性,20 名女性),年龄 67.1 ± 10.6 岁,BMI 32.5 ± 5.2,A1c 8.2 ± 1.2%,eGFR 73 ± 27.2 ml/min,血糖/C 肽比值为 60.7 ± 46.4。总组中有 59%的患者正在服用胰岛素分泌剂。根据平均 eGFR 和是否使用胰岛素分泌剂将患者分为两组。在 eGFR 最低的患者中(<50 ml/min),血糖/C 肽比值最低。
肾功能下降和年龄增长与血糖/C 肽比值最低有关,与血糖控制无关。在使用类似分泌剂的情况下,当 eGFR 为 ≤49 ml/min 时,血糖/C 肽比值低于>50-80 ml/min。分泌剂的使用与血糖/C 肽水平降低有关。在肾功能下降的患者(eGFR <50 ml/min)中,使用胰岛素分泌剂可能与低血糖反应风险增加相关的更低的血糖/C 肽比值有关。